Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16 at 10:55 a.m. Eastern Time.
The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Julie Normart (media) Pure Communications 415-946-1087 [email protected]
